pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kisunla
drug
save

donanemab

Marketedupdated 6mo ago
by Eli Lilly and Co
Approved
community read0 votes

indications

investigational
Alzheimer's Disease

all catalysts(0)

nothing on the calendar yet

Trials studying donanemab

  • phase2A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)recruitingn=350
  • —A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Diseaserecruitingn=6,250
  • phase4A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Diseasenot yet recruitingn=50
  • phase3A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)active not recruitingn=1,500
  • phase3A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)active not recruitingn=1,736
  • phase3Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Diseaserecruitingn=140
  • phase2Alzheimer's Tau Platform: Regimen A - AADvac1not yet recruitingn=450
  • phase2A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)completedn=272

News(10)

  • Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
    This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.
    biospace · 1d ago
  • London biotech Oyster harvests $60M for tau-targeting brain drugs
    Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
    biopharma_dive · 7d ago
  • Opinion: STAT+: What it’s like to live with cognitively unimpaired Alzheimer’s disease
    People with cognitively unimpaired Alzheimer’s “may be asymptomatic, but they do have a disease experience,” writes Jason Karlawish.
    stat · 11d ago
  • Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
    Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…
    fiercebiotech · 19d ago
  • Drug prices climb past $250K as US patients balk at the pharmacy
    Just one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the pro…
    biospace · 26d ago
  • Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
    In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.
    biopharma_dive · 1mo ago
  • Eli Lilly and the LA Dodgers: A tale of 2 dynasties
    Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
    biospace · 1mo ago
  • Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
    Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.
    fiercebiotech · 2mo ago
  • BMS’ neuro renaissance was built on back of Celgene mega-merger
    Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychi…
    biospace · 2mo ago
  • Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
    With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
    biospace · 3mo ago
view all news mentions →
brand
Kisunla
generic
donanemab-azbt
indication
Alzheimer's Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?